Mirati Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, MRTX, Mirati Therapeutics Inc, priceseries

Mirati Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
83.39
Close
81.46
High
86.47
Low
80.63
Previous Close
83.01
Daily Price Gain
-1.55
YTD High
151.15
YTD High Date
Jan 3, 2022
YTD Low
80.63
YTD Low Date
Mar 7, 2022
YTD Price Change
-69.51
YTD Gain
-46.04%
52 Week High
200.95
52 Week High Date
Mar 9, 2021
52 Week Low
80.63
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-109.87
52 Week Gain
-57.42%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 7. 2017
5.40
Feb 22. 2017
5.79
10 Trading Days
7.30%
Link
LONG
Jun 19. 2017
3.40
Jun 28. 2017
3.67
7 Trading Days
8.06%
Link
LONG
Jul 12. 2017
3.70
Aug 2. 2017
4.79
15 Trading Days
29.43%
Link
LONG
Sep 25. 2017
10.10
Oct 16. 2017
13.82
15 Trading Days
36.82%
Link
LONG
Jan 9. 2018
19.05
Jan 30. 2018
25.78
14 Trading Days
35.34%
Link
LONG
Feb 5. 2018
27.00
Feb 8. 2018
28.75
3 Trading Days
6.48%
Link
LONG
Mar 2. 2018
28.45
Mar 19. 2018
32.44
11 Trading Days
14.04%
Link
LONG
May 8. 2018
33.25
Jun 4. 2018
39.86
18 Trading Days
19.88%
Link
LONG
Jun 12. 2018
46.35
Jun 25. 2018
49.50
9 Trading Days
6.80%
Link
LONG
Jul 19. 2018
51.00
Aug 3. 2018
58.87
11 Trading Days
15.42%
Link
LONG
Dec 26. 2018
39.51
Jan 28. 2019
62.93
21 Trading Days
59.28%
Link
LONG
Jan 30. 2019
65.45
Feb 28. 2019
72.57
20 Trading Days
10.88%
Link
LONG
Jun 3. 2019
89.20
Jul 9. 2019
104.80
25 Trading Days
17.49%
Link
LONG
Oct 25. 2019
80.84
Nov 15. 2019
96.83
15 Trading Days
19.78%
Link
LONG
Nov 25. 2019
95.56
Dec 12. 2019
101.16
12 Trading Days
5.87%
Link
LONG
Apr 8. 2020
79.01
Apr 21. 2020
85.95
8 Trading Days
8.79%
Link
LONG
May 4. 2020
91.37
May 19. 2020
100.85
11 Trading Days
10.37%
Link
LONG
Jun 18. 2020
108.86
Jul 9. 2020
116.26
14 Trading Days
6.80%
Link
LONG
Aug 12. 2020
131.59
Sep 2. 2020
146.53
15 Trading Days
11.35%
Link
LONG
Sep 14. 2020
145.74
Oct 2. 2020
163.84
14 Trading Days
12.42%
Link
LONG
Oct 5. 2020
168.49
Oct 21. 2020
184.78
12 Trading Days
9.67%
Link
LONG
Oct 26. 2020
196.68
Nov 10. 2020
216.07
11 Trading Days
9.86%
Link
LONG
Aug 23. 2021
145.16
Sep 9. 2021
167.30
12 Trading Days
15.25%
Link
Company Information
Stock Symbol
MRTX
Exchange
NasdaqCM
Company URL
http://www.mirati.com
Company Phone
858-332-3410
CEO
Charles M. Baum
Headquarters
California
Business Address
9393 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001576263
About

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company focuses on developing a pipeline of oncology products to treat genetic and epigenetic drivers of cancer in selected subsets of cancer patients .Its product candidates include glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

Description

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading